{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:34:13Z","timestamp":1785929653050,"version":"3.56.0"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the S&T Program of Chengde","award":["202303A064"],"award-info":[{"award-number":["202303A064"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"abstract":"<jats:p>This study aimed to identify adverse event signals associated with romidepsin using data from the Food and Drug Administration Adverse Event Reporting System to provide evidence supporting drug safety in clinical practice. Adverse event reports were extracted from the Food and Drug Administration Adverse Event Reporting System covering the period from the 3rd quarter of 2009 to the 4th quarter of 2024. Risk signals were analyzed using 4 disproportionality algorithms: the Bayesian geometric mean, reporting odds ratio, Bayesian confidence propagation neural network, and proportional reporting ratio. A total of 1545 romidepsin-related adverse event reports were identified. Disproportionality analysis revealed 21 system organ classes and 125 preferred terms associated with romidepsin. Commonly reported adverse events included thrombocytopenia, anemia, QT interval prolongation, and neutropenia. Several additional events not listed on the drug label were also detected, such as cardiac tamponade, elevated troponin I, and mental status changes. These findings contribute to the ongoing evaluation of the safety profile of romidepsin and can inform clinical monitoring and risk assessment. The newly identified adverse events warrant further investigation to elucidate their underlying mechanisms.<\/jats:p>","DOI":"10.1097\/md.0000000000047449","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T17:01:02Z","timestamp":1769965262000},"page":"e47449","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A real-world retrospective study of romidepsin: Insights from the Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1097","volume":"105","author":[{"given":"Yunwei","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Oncology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Du","sequence":"additional","affiliation":[{"name":"Experimental Center of Molecular Biology, Chengde Medical University, Chengde, Hebei, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chengde Sixth Hospital, Chengde, Hebei, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weining","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, PR China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, PR China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3463-5667","authenticated-orcid":false,"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, PR China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260519","first-page":"7","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R2-20260519","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3390\/cells11030552","article-title":"Oxidative stress in human pathology and aging: molecular mechanisms and perspectives.","volume":"11","author":"Hajam","year":"2022","journal-title":"Cells"},{"key":"R3-20260519","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/14737140.2018.1409624","article-title":"Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.","volume":"18","author":"Nagasaka","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"R4-20260519","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jjco\/hyaa268","article-title":"The role of radiotherapy in the age of immunotherapy.","volume":"51","author":"Sato","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"R5-20260519","doi-asserted-by":"crossref","first-page":"1073274817744621","DOI":"10.1177\/1073274817744621","article-title":"Liver resection and surgical strategies for management of primary liver cancer.","volume":"25","author":"Orcutt","year":"2018","journal-title":"Cancer Control"},{"key":"R6-20260519","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy.","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R7-20260519","doi-asserted-by":"crossref","first-page":"115938","DOI":"10.1016\/j.ejmech.2023.115938","article-title":"Dual inhibitors of HDAC and other epigenetic regulators: a novel strategy for cancer treatment.","volume":"263","author":"Shirbhate","year":"2024","journal-title":"Eur J Med Chem"},{"key":"R8-20260519","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers.","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R9-20260519","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ceb.2018.01.003","article-title":"The epigenetic basis of cellular plasticity.","volume":"49","author":"Paksa","year":"2017","journal-title":"Curr Opin Cell Biol"},{"key":"R10-20260519","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/cancers11030304","article-title":"Inhibition of BET proteins and histone deacetylase (HDACs): crossing roads in cancer therapy.","volume":"11","author":"Manzotti","year":"2019","journal-title":"Cancers"},{"key":"R11-20260519","doi-asserted-by":"crossref","first-page":"576391","DOI":"10.3389\/fcell.2020.576391","article-title":"Recent update of HDAC inhibitors in lymphoma.","volume":"8","author":"Chen","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"R12-20260519","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors.","volume":"17","author":"Shi","year":"2024","journal-title":"J Hematol Oncol"},{"key":"R13-20260519","doi-asserted-by":"crossref","first-page":"114774","DOI":"10.1016\/j.biopha.2023.114774","article-title":"Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin.","volume":"164","author":"El Omari","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"R14-20260519","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-020-02653-1","article-title":"Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer.","volume":"70","author":"Shi","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"R16-20260519","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.biopha.2016.04.053","article-title":"Histone deacetylase inhibitor, romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.","volume":"82","author":"Li","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"R18-20260519","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2012.09.016","article-title":"Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.","volume":"127","author":"Wilson","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R19-20260519","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/15384047.2016.1219820","article-title":"The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines.","volume":"17","author":"Cosenza","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"R20-20260519","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bcp.2016.12.008","article-title":"Romidepsin induces G2\/M phase arrest via Erk\/cdc25C\/cdc2\/cyclinB pathway and apoptosis induction through JNK\/c-Jun\/caspase3 pathway in hepatocellular carcinoma cells.","volume":"127","author":"Sun","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"R21-20260519","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: emerging indications and novel molecules.","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R23-20260519","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/1078-0432.CCR-07-0135","article-title":"Clinical and molecular responses in lung cancer patients receiving Romidepsin.","volume":"14","author":"Schrump","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R24-20260519","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1158\/1078-0432.CCR-08-1007","article-title":"Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.","volume":"14","author":"Odenike","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R25-20260519","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/annonc\/mdp270","article-title":"Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).","volume":"21","author":"Molife","year":"2010","journal-title":"Ann Oncol"},{"key":"R26-20260519","doi-asserted-by":"crossref","first-page":"1369384","DOI":"10.3389\/fphar.2024.1369384","article-title":"Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database.","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"R27-20260519","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","article-title":"Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database.","volume":"347","author":"Zhu","year":"2024","journal-title":"J Affect Disord"},{"key":"R28-20260519","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system.","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"R29-20260519","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40618-014-0227-x","article-title":"Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves\u2019 orbitopathy.","volume":"38","author":"Riedl","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"R30-20260519","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12911-023-02375-1","article-title":"Evaluating MedDRA-to-ICD terminology mappings.","volume":"23","author":"Zhang","year":"2024","journal-title":"BMC Med Inform Decis Mak"},{"key":"R31-20260519","doi-asserted-by":"crossref","first-page":"101535","DOI":"10.1016\/j.eclinm.2022.101535","article-title":"Toxicity spectrum of immunotherapy in advanced lung cancer: a safety analysis from clinical trials and a pharmacovigilance system.","volume":"50","author":"Yan","year":"2022","journal-title":"EClinicalMedicine"},{"key":"R32-20260519","doi-asserted-by":"crossref","first-page":"1266890","DOI":"10.3389\/fphar.2023.1266890","article-title":"Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study.","volume":"14","author":"Yuan","year":"2023","journal-title":"Front Pharmacol"},{"key":"R33-20260519","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records.","volume":"33","author":"Kim","year":"2018","journal-title":"J Korean Med Sci"},{"key":"R34-20260519","doi-asserted-by":"crossref","first-page":"1563797","DOI":"10.3389\/fphar.2025.1563797","article-title":"Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess.","volume":"16","author":"Yin","year":"2025","journal-title":"Front Pharmacol"},{"key":"R35-20260519","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1080\/02648725.2023.2202541","article-title":"Propofol-associated serious adverse events: an analysis of the FAERS database.","volume":"40","author":"Xuan","year":"2024","journal-title":"Biotechnol Genet Eng Rev"},{"key":"R36-20260519","doi-asserted-by":"crossref","first-page":"9218","DOI":"10.1038\/s41598-025-92741-y","article-title":"Disproportionality analysis of post-marketing safety concerns associated with selumetinib in the FDA adverse event reporting system.","volume":"15","author":"Liu","year":"2025","journal-title":"Sci Rep"},{"key":"R37-20260519","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio.","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R38-20260519","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation.","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R39-20260519","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7150\/ijms.7967","article-title":"Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.","volume":"11","author":"Sakaeda","year":"2014","journal-title":"Int J Med Sci"},{"key":"R40-20260519","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R41-20260519","doi-asserted-by":"crossref","first-page":"732727","DOI":"10.3389\/fmed.2021.732727","article-title":"Efficacy and treatment-related adverse events of romidepsin in PTCL clinical studies: a systematic review and meta-analysis.","volume":"8","author":"Du","year":"2021","journal-title":"Front Med"},{"key":"R42-20260519","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1158\/1078-0432.CCR-13-0109","article-title":"Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.","volume":"19","author":"Noonan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R43-20260519","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.","volume":"10","author":"Grant","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"R44-20260519","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","article-title":"Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.","volume":"12","author":"Piekarz","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R45-20260519","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology.","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf"},{"key":"R46-20260519","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2146\/130024","article-title":"Reversible ageusia associated with romidepsin therapy.","volume":"70","author":"Cooper","year":"2013","journal-title":"Am J Health-Syst Pharm"},{"key":"R47-20260519","first-page":"209","article-title":"Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed\/refractory T-cell lymphoma: results from a phase I\/II open-label multicenter study.","volume":"109","author":"Iyer","year":"2024","journal-title":"Haematologica"},{"key":"R48-20260519","first-page":"1081","article-title":"A systematic review of dysgeusia induced by cancer therapies.","volume":"18","author":"Hovan","year":"2010","journal-title":"Support Care Cancer"},{"key":"R49-20260519","first-page":"58","article-title":"Taste and odor abnormalities in cancer patients.","volume":"7","author":"Hong","year":"2009","journal-title":"J Support Oncol"},{"key":"R50-20260519","first-page":"5351","article-title":"Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer.","volume":"30","author":"Ito","year":"2022","journal-title":"Support Care Cancer"},{"key":"R51-20260519","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0024-3205(70)90278-X","article-title":"Hypogeusia corrected by Ni++ and Zn++.","volume":"9","author":"Henkin","year":"1970","journal-title":"Life Sci II"},{"key":"R52-20260519","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3950\/jibiinkoka.116.17","article-title":"The effect of zinc agent in 219 patients with zinc deficiency-inductive\/idiopathic taste disorder: a placebo controlled randomized study.","volume":"116","author":"Ikeda","year":"2013","journal-title":"Nihon Jibiinkoka Gakkai Kaiho"},{"key":"R53-20260519","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/1568026619666190122144949","article-title":"Zinc-dependent deacetylase (HDAC) inhibitors with different zinc binding groups.","volume":"19","author":"Li","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"R54-20260519","doi-asserted-by":"crossref","first-page":"19559","DOI":"10.18632\/oncotarget.7195","article-title":"Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.","volume":"7","author":"Ciardiello","year":"2016","journal-title":"Oncotarget"},{"key":"R55-20260519","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/eji.201141800","article-title":"Downregulation of MUC1 expression and its recognition by CD8\u207a T cells on the surface of malignant pleural mesothelioma cells treated with HDACi.","volume":"42","author":"Roulois","year":"2012","journal-title":"Eur J Immunol"},{"key":"R56-20260519","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.4049\/jimmunol.179.12.8235","article-title":"Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of Jurkat T cells.","volume":"179","author":"Andresen","year":"2007","journal-title":"J Immunol"},{"key":"R57-20260519","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade.","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R58-20260519","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/ajt.14749","article-title":"Histone\/protein deacetylase inhibitor therapy for enhancement of Foxp3+ T-regulatory cell function posttransplantation.","volume":"18","author":"Wang","year":"2018","journal-title":"Am J Transpl"},{"key":"R59-20260519","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.coi.2011.07.002","article-title":"Histone\/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells.","volume":"23","author":"Beier","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"R60-20260519","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/tri.12265","article-title":"Improving allogeneic islet transplantation by suppressing Th17 and enhancing Treg with histone deacetylase inhibitors.","volume":"27","author":"Sugimoto","year":"2014","journal-title":"Transpl Int"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:03:31Z","timestamp":1779195811000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047449","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"2025-09-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}